Keros Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Lexington, MA
KROS chart
What traders are saying about $KROS
Latest postsKeros Therapeutics, Inc. news
- BlackRock reports a Keros Therapeutics (KROS) stake with sole voting power over 1.58M shares.
Stock Titan ·
- Weekly Recap: Milestone payment and Phase II rinvatercept DMD trial
TradingView ·
- Avoiding Lag: Real-Time Signals in (KROS) Movement
Stock Traders Daily ·
- Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Rated "Hold" by Sell-Side Brokerages
MarketBeat ·
- Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to Strong Sell
MarketBeat ·
- Keros Therapeutics, Inc. Estimates – NASDAQ:KROS
TradingView ·
- Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
marketbeat.com ·
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Yahoo Finance ·
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Yahoo Finance ·
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Yahoo Finance ·
- Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Yahoo Finance ·
- Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Yahoo Finance ·
Keros Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151,000 | $0 |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M |
| Diluted EPS | $2.30 | $-5.00 | $-5.20 | $-4.15 |
| Total assets (year end) | $338.0M | $615.9M | $370.0M | $306.8M |
| Cash and equivalents (year end) | $287.4M | $559.9M | $331.1M | $279.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Keros Therapeutics, Inc.
- Ticker
- KROS (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Lexington, MA
- Fiscal year end
- December 31
- SEC CIK
- 1664710
Frequently asked questions
What exchange is Keros Therapeutics, Inc. listed on?
Keros Therapeutics, Inc. trades on the Nasdaq under the ticker symbol KROS.
What industry is Keros Therapeutics, Inc. in?
Keros Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Keros Therapeutics, Inc. headquartered?
Keros Therapeutics, Inc.'s business address on file with the SEC is in Lexington, MA.
When does Keros Therapeutics, Inc.'s fiscal year end?
Keros Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Keros Therapeutics, Inc. report?
Keros Therapeutics, Inc. reported $244.1M in revenue for calendar year 2025, according to its SEC filings.